Leukemia Research Initiatives
Our commitment to leukemia research is echoed through two major programs:
CLL Moon Shot
Our high-powered, offensive approach dedicated to making enormous strides the treatment of CLL.
Monoclonal Antibody Drug for ALL
MD Anderson participated in a Phase III randomized trial revealing longer overall survival for advanced acute lymphoblastic leukemia (ALL) patients treated with blinatumomab.
Immunotherapy Improves AML Survival
The immunotherapy drug nivolumab in combination with standard chemotherapy more than doubled response rates and improved overall survival in patients with acute myeloid leukemia (AML).
Combination Therapy Shows Promise for CML
Preclinical research reveals that combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) may stall disease progression.